ATRIUM THERAPEUTICS INC (RNA) — insider trading
Health Care · NASDAQ
ATRIUM THERAPEUTICS INC (RNA) has 25 reported SEC Form 4 insider transactions in our data (latest 2026-09-18).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Younis Husam | Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 11,216 | $8.95 | $100.4K | Form 4 |
| 2026-09-18 | Hughes Steven George | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 21,459 | $8.95 | $192.1K | Form 4 |
| 2026-09-18 | Flanagan W. Michael | Director | Shares withheld for taxes / exercise cost | 22,812 | $8.95 | $204.2K | Form 4 |
| 2026-09-18 | Boyce Sarah | Director | Shares withheld for taxes / exercise cost | 126,418 | $8.95 | $1.13M | Form 4 |
| 2026-09-18 | Kenney Stephanie | Officer (See Remarks) | Shares withheld for taxes / exercise cost | 2,375 | $8.95 | $21.3K | Form 4 |
| 2026-09-18 | Gallagher Kathleen P. | Director, Officer (See Remarks) | Shares withheld for taxes / exercise cost | 11,632 | $8.95 | $104.1K | Form 4 |
| 2026-09-18 | Winslow Brendan R. | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 6,742 | $8.95 | $60.3K | Form 4 |
| 2026-09-18 | Hoyos Rocio Martin | Officer (Chief Strategy Officer) | Shares withheld for taxes / exercise cost | 8,320 | $8.95 | $74.5K | Form 4 |
| 2026-04-20 | Younis Husam | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-20 | Younis Husam | Officer (Chief Scientific Officer) | Grant / award / vesting | 30,000 | — | $0 | Form 4 |
| 2026-04-20 | Hoyos Rocio Martin | Officer (Chief Strategy Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-20 | Hoyos Rocio Martin | Officer (Chief Strategy Officer) | Grant / award / vesting | 30,000 | — | $0 | Form 4 |
| 2026-04-20 | Gallagher Kathleen P. | Director, Officer (See Remarks) | Grant / award / vesting (derivative) | 205,000 | — | $0 | Form 4 |
| 2026-04-20 | Gallagher Kathleen P. | Director, Officer (See Remarks) | Grant / award / vesting | 102,500 | — | $0 | Form 4 |
| 2026-04-20 | Winslow Brendan R. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-20 | Winslow Brendan R. | Officer (Chief Financial Officer) | Grant / award / vesting | 30,000 | — | $0 | Form 4 |
| 2026-04-20 | Hughes Steven George | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-20 | Hughes Steven George | Officer (Chief Medical Officer) | Grant / award / vesting | 30,000 | — | $0 | Form 4 |
| 2026-04-20 | Kenney Stephanie | Officer (See Remarks) | Grant / award / vesting (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-04-20 | Kenney Stephanie | Officer (See Remarks) | Grant / award / vesting | 30,000 | — | $0 | Form 4 |
| 2026-02-27 | Skerjanec Simona | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-02-27 | Flanagan W. Michael | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-02-27 | WILSON TROY EDWARD | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-02-27 | BOESS CARSTEN | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-02-27 | Boyce Sarah | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
Ask the chat about RNA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ATRIUM THERAPEUTICS INC (RNA).
Last updated 2026-09-18 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.